

**Table SI. Characteristics of the study population (n = 3,771)**

Female, n (%)	2,422 (64.2)
Age, years, mean ± SD	54.1 ± 17.8
Methotrexate dose/week (mg), median [IQR]	12.2 [9.3–16.0]
Oral use, n (%)	2,708 (71.8)
Duration of methotrexate use (days), median [IQR]	614 [164–1526]
Underlying disease, n (%)	
Rheumatoid arthritis	1,068 (28.3)
Psoriasis/psoriatic arthritis	880 (23.3)
Crohn's disease or ulcerative colitis	140 (3.7)
Combination of several diseases	801 (21.3)
Other or unknown	882 (23.4)
Prescriber specialty, n (%)	
Rheumatologist	1,635 (43.4)
General practitioner	1,387 (36.8)
Dermatologist	209 (5.5)
Gastroenterologist	25 (0.6)
Internist	67 (1.8)
Other	448 (11.9)
Prescriber practice localization, n (%)	
Hospital	989 (26.2)
Community	2,014 (53.4)
Hospital and community	338 (9.0)
Unknown	430 (11.4)
Co-prescription of systemic glucocorticoids, n (%)	1,705 (45.2)
Adequate co-prescription of folate, n (%)	2,774 (73.6)

IQR: interquartile range; SD: standard deviation.